Related Experiment Video
Updated: May 5, 2026
08:55
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
13.8K
Time-Resolved Transcriptomic Profiling of Surgical Wounds Identifies Stage-Specific Therapeutic Targets for Residual
Seongyun Lim1, Young-Jae Cho2, Myeong-Seon Kim3
1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea.
Pharmaceutics
|May 4, 2026
Summary
Surgical wounding after ovarian cancer surgery creates temporary changes that may help tumors grow and resist drugs. Specific drugs can counteract these effects at different healing stages.
Area of Science:
- Oncology
- Translational Medicine
- Genomics
Background:
- Adjuvant chemotherapy timing after epithelial ovarian cancer surgery is unclear.
- Perioperative wound healing may create a pro-tumorigenic microenvironment, impacting drug resistance.
- Understanding wound-induced changes is crucial for optimizing cancer therapy.
Purpose of the Study:
- To characterize time-dependent transcriptomic alterations induced by surgical wounding in ovarian cancer.
- To identify pharmacologic agents capable of reversing these wound-induced responses.
- To inform time-adapted perioperative strategies for ovarian cancer treatment.
Main Methods:
- Utilized an ID8 murine ovarian cancer model comparing no treatment, anesthesia alone, and surgical wounding.
- Performed RNA sequencing at baseline, 1 day, 1 week, and 2 weeks post-intervention.
- Defined wound-specific differentially expressed genes (WsDEGs) and conducted drug repurposing using the REMEDY platform.
Main Results:
- Surgical wounding increased tumor burden and induced distinct, time-dependent transcriptomic programs.
- Early wound responses (T1) involved inflammation and angiogenesis, targeted by Vorinostat and Homoharringtonine.
- Later responses (T2, T3) involved cell survival, cycle regulation, and lipid metabolism, with potential modulators including LY-2090314, Artesunate, Birinapant, Fulvestrant, Atorvastatin, Imatinib, and ABT-737.
Conclusions:
- Perioperative surgical wounding dynamically alters the tumor microenvironment in a stage-specific manner.
- These transcriptomic changes can potentially promote ovarian cancer progression and affect drug responsiveness.
- Time-adapted perioperative pharmacologic interventions may optimize postoperative cancer therapy outcomes.
